Advances and challenges in pharmacotherapeutics for amphetamine-type stimulants addiction
Abstract
Addiction to amphetamine-type stimulants (ATS) is a serious worldwide public health problem with major medical, psychiatric and socioeconomic consequences. However, no approved pharmacological therapies are available to treat ATS addiction. Based on the neurobiological mechanisms underlying ATS addiction, the recent research works about pharmacological strategies have been focused on monoamine, glutamate, endogenous opioid peptide and γ-amino butyric acid (GABA) systems. This review summarizes the recent advances in the medications being developed to treat ATS addiction and discusses the remaining challenges. Although no substantial evidence for efficacious medications has emerged, some of these agents, including bupropion, naltrexone and mirtazapine, have demonstrated promise in clinical studies. Moreover, some challenges, such as the development of new preclinical animal models of drug addiction, the design of large-scale clinical trials with strict quality control, and the distinction of patients' genetic polymorphisms, need further attention. Despite the lack of success to date, much effort is being made to develop efficacious medications for treating ATS addiction.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Severe addiction to amphetamine and its analogs is a worldwide public health problem that extensively limits their applications.
“However, severe addiction to amphetamine and its analogs (called amphetamine-type stimulants, such as methamphetamine) has become a worldwide public health problem, extensively limiting their applications (8).”
Cites
A Double-Blind, Placebo-Controlled Trial of Modafinil for Cocaine Dependence
Dackis, C. A., Kampman, K. M., Lynch, K. G., Pettinati, H. M., & O'Brien, C. P. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300600 · Cited by 391 · see citing works
Pharmacological approaches to methamphetamine dependence: a focused review
Karila, L., Weinstein, A., Aubin, H., Benyamina, A., Reynaud, M., & Batki, S. L. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03639.x · Cited by 242 · see citing works
Bupropion for the treatment of methamphetamine dependence
Elkashef, A. M., Rawson, R. A., Anderson, A. L., Li, S.-H., Holmes, T., Smith, E. V., Chiang, N., Kahn, R., Vocci, F., Ling, W., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301481 · Cited by 234 · see citing works
A double-blind, placebo-controlled trial of modafinil for cocaine dependence
Dackis, C. A., Kampman, K. M., Lynch, K. G., Plebani, J. G., Pettinati, H. M., Sparkman, T., & O'Brien, C. P. (2012) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2011.12.014 · Cited by 187 · see citing works
Naltrexone for the Treatment of Amphetamine Dependence: A Randomized, Placebo-Controlled Trial
Jayaram-Lindström, N., Hammarberg, A., Beck, O., & Franck, J. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08020304 · Cited by 185 · see citing works
Mirtazapine to Reduce Methamphetamine Use: A Randomized Controlled Trial
Colfax, G. N. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.124 · Cited by 175 · see citing works
Rose, M. E., & Grant, J. E. (2008) · Annals of Clinical Psychiatry · doi:10.1080/10401230802177656 · Cited by 121 · see citing works
McGregor, C., Srisurapanont, M., Mitchell, A., Wickes, W., & White, J. M. (2008) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2007.12.003 · Cited by 82 · see citing works
Nejtek, V. A., Avila, M., Chen, L.-A., Zielinski, T., Djokovic, M., Podawlitz, A., Kaiser, K., Bae, S., & Rush, A. J. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0808 · Cited by 69 · see citing works
McElhiney, M. C., Rabkin, J. G., Rabkin, R., & Nunes, E. V. (2009) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990802342907 · Cited by 61 · see citing works
An Open-Label Pilot Study of Risperidone in the Treatment of Methamphetamine Dependence
Meredith, C. W., Jaffe, C., Yanasak, E., Cherrier, M., & Saxon, A. J. (2007) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2007.10399875 · Cited by 37 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Jian-min, C., Zhi-yuan, W., Shi-xuan, W., Rui, S., Ning, W., & Jin, L. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.885574 · Cited by 7 · see citing works
“However, severe addiction to amphetamine and its analogs (called amphetamine-type stimulants, such as methamphetamine) has become a worldwide public health problem, extensively limiting their applications (8).”
Background
- Authors
- Cao, D.-N., Shi, J.-J., Hao, W., Wu, N., & Li, J.
- Affiliations
- Second Xiangya Hospital of Central South University (CN)
- Corresponding author
- Wu, Ning
- Li, Jin
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 780
- Pages
- 129-135
- ISSN
- 0014-2999 (ISSN-L)
- OpenAlex
- W2311690815
- Cited by
- 34
- References
- 11
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 1 · 2023: 3 · 2022: 3 · 2021: 1 · 2020: 3 · 2019: 5 · 2018: 8 · 2017: 2
- FWCI
- 0.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Basic Research Program of China (2015CB553504)
- Key Project of Beijing Natural Science Foundation (7131010)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- amphetamine-type stimulants, drug addiction, pharmacotherapy, monoaminergic systems, glutamatergic system, endogenous opioids, GABA system, bupropion, naltrexone, mirtazapine, animal models of addiction, genetic polymorphism, clinical trial design
- MeSH terms
- Animals, Humans, Amphetamine-Related Disorders, Drug Discovery, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
